Ku Yonson, Tominaga Masahiro, Iwasaki Takeshi, Fukumoto Takumi, Kuroda Yoshikazu
Department of Gastroenterological Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Int J Clin Oncol. 2002 Apr;7(2):82-90. doi: 10.1007/s101470200011.
Treatment failure with conventional approaches, including systemic and regional chemotherapy, for refractory advanced primary or metastatic hepatic cancers has evoked periodic waves of enthusiasm for isolated hepatic perfusion (IHP) over the past 50 years. With technical refinements of the procedure and the introduction of a novel biochemical regimen combining tumor necrosis factor and melphalan, several hepatobiliary-oncological centers initiated clinical trials of IHP in the 1990s. In parallel, a percutaneous technique of IHP has been developed in this era as a minimally invasive, simple form of IHP, and phase I and II studies have been done in some specialized centers. This study attempts to review past and current techniques of IHP, and to outline their possible role in the treatment of unresectable hepatic tumors, with special reference to hepatocellular carcinoma and colorectal hepatic metastases.
在过去50年里,包括全身化疗和区域化疗在内的传统方法治疗难治性晚期原发性或转移性肝癌失败后,孤立肝灌注(IHP)不时引发人们的热情。随着该手术技术的改进以及一种将肿瘤坏死因子和美法仑联合使用的新型生化方案的引入,20世纪90年代,多个肝胆肿瘤中心启动了IHP的临床试验。与此同时,这一时期还开发了一种经皮IHP技术,作为一种微创、简单的IHP形式,一些专业中心已开展了I期和II期研究。本研究旨在回顾IHP过去和当前的技术,并概述其在不可切除性肝肿瘤治疗中的可能作用,特别提及肝细胞癌和结直肠癌肝转移。